Q1 Earnings Forecast for MacroGenics Issued By HC Wainwright

MacroGenics, Inc. (NASDAQ:MGNX) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for MacroGenics in a report released on Monday, November 3rd. HC Wainwright analyst R. Burns anticipates that the biopharmaceutical company will post earnings of ($0.72) per share for the quarter. HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics’ Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.76) EPS and Q4 2026 earnings at ($0.78) EPS.

A number of other equities research analysts also recently commented on the company. Barclays assumed coverage on MacroGenics in a research report on Wednesday, September 17th. They issued an “overweight” rating and a $3.00 target price on the stock. Wall Street Zen cut MacroGenics from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd. Leerink Partners dropped their price objective on MacroGenics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MacroGenics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MacroGenics has a consensus rating of “Hold” and a consensus price target of $3.60.

MacroGenics Stock Down 4.8%

NASDAQ:MGNX opened at $1.58 on Tuesday. MacroGenics has a 52 week low of $0.99 and a 52 week high of $5.10. The company has a market capitalization of $99.87 million, a P/E ratio of -2.77 and a beta of 1.61. The stock’s fifty day moving average is $1.73 and its two-hundred day moving average is $1.60.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.02. MacroGenics had a negative return on equity of 40.24% and a negative net margin of 21.99%.The company had revenue of $22.24 million for the quarter, compared to the consensus estimate of $28.06 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MGNX. GSA Capital Partners LLP grew its stake in MacroGenics by 81.9% during the 1st quarter. GSA Capital Partners LLP now owns 448,530 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 201,926 shares in the last quarter. Deutsche Bank AG grew its stake in MacroGenics by 3,803.2% during the 1st quarter. Deutsche Bank AG now owns 51,093 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 49,784 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in MacroGenics by 9.6% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 816,054 shares of the biopharmaceutical company’s stock worth $1,036,000 after purchasing an additional 71,152 shares in the last quarter. Invesco Ltd. grew its stake in MacroGenics by 90.0% during the 1st quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 32,398 shares in the last quarter. Finally, Nuveen LLC acquired a new position in MacroGenics during the 1st quarter worth $252,000. 96.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at MacroGenics

In other news, Director William K. Heiden acquired 49,500 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average cost of $1.49 per share, with a total value of $73,755.00. Following the completion of the purchase, the director owned 111,000 shares of the company’s stock, valued at $165,390. This represents a 80.49% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders own 13.00% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.